We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

231 hedge funds and large institutions have $2.61B invested in Axsome Therapeutics in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 90 increasing their positions, 54 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 16

75% more call options, than puts

Call options by funds: $106M | Put options by funds: $60.5M

67% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 54

33% more capital invested

Capital invested by funds: $1.97B → $2.61B (+$647M)

17% more funds holding

Funds holding: 197 → 231 (+34)

4.83% more ownership

Funds ownership: 73.31% → 78.14% (+4.8%)

11% less funds holding in top 10

Funds holding in top 10: 9 → 8 (-1)

Holders
231
Holders Change
+34
Holders Change %
+17.26%
% of All Funds
3.63%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.13%
New
50
Increased
90
Reduced
54
Closed
16
Calls
$106M
Puts
$60.5M
Net Calls
+$45.1M
Net Calls Change
+$22.7M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$73.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$56.4M
3
RI
RTW Investments
New York
+$37.1M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$34M
5
DTC
Deep Track Capital
Connecticut
+$28.3M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$51.8M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$44.7M
3
Holocene Advisors
Holocene Advisors
New York
-$32.6M
4
Millennium Management
Millennium Management
New York
-$22.4M
5
WP
Woodline Partners
California
-$9.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$23.2M -$9.18M -124,455 -28%
TCM
27
Tang Capital Management
California
$23M – – –
IAM
28
Iridian Asset Management
Connecticut
$22.4M +$1.6M +21,636 +7%
Jane Street
29
Jane Street
New York
$19.8M +$18.7M +254,158 +1,169%
FCM
30
Farallon Capital Management
California
$19.6M +$20.1M +272,800 New
PA
31
Perceptive Advisors
New York
$19.5M +$20M +271,493 New
Charles Schwab
32
Charles Schwab
California
$19.3M +$1.42M +19,296 +8%
DCM
33
Driehaus Capital Management
Illinois
$17.9M +$6.07M +82,267 +49%
FCM
34
Frontier Capital Management
Massachusetts
$16M +$13.4M +181,515 +446%
Norges Bank
35
Norges Bank
Norway
$15.1M – – –
TLP
36
Tri Locum Partners
New York
$14.4M +$3.75M +50,875 +34%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$14.4M +$14.7M +199,711 New
Marshall Wace
38
Marshall Wace
United Kingdom
$13.8M +$13.6M +184,390 +2,589%
SEI Investments
39
SEI Investments
Pennsylvania
$13.2M +$4.44M +60,158 +48%
SI
40
Sofinnova Investments
California
$12.9M +$4.3M +58,346 +48%
JP Morgan Chase
41
JP Morgan Chase
New York
$12.4M -$68.2K -924 -0.5%
Invesco
42
Invesco
Georgia
$12.3M +$8.19M +111,045 +183%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$11.6M +$2.65M +35,970 +29%
Goldman Sachs
44
Goldman Sachs
New York
$10.1M -$9.54M -129,381 -48%
US Bancorp
45
US Bancorp
Minnesota
$10M +$313K +4,241 +3%
CS
46
Clear Street
New York
$9.45M +$9.7M +131,500 New
Alyeska Investment Group
47
Alyeska Investment Group
Illinois
$8.98M +$9.22M +125,000 New
CC
48
Cannell & Co
New York
$8.57M – – –
PI
49
Putnam Investments
Massachusetts
$8.43M +$183K +2,487 +2%
ACM
50
Atika Capital Management
New York
$8.05M -$3.17M -43,000 -28%
1
2
3 4 5

AXSM Hedge Fund Activity: Q2 2023 in Review

231 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2023, worth a combined $2.61B — up 33% from $1.97B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new AXSM positions and 16 closed out — a net gain of 34 holders — while 90 added to existing stakes and 54 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $73.8M. The largest seller was Point72 Asset Management, cutting an estimated $51.8M.

  • 231 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2023, up from 197 in Q1 2023.
  • Funds reported $2.61B of Axsome Therapeutics stock for Q2 2023, up 33% quarter-over-quarter.
  • 50 funds opened new Axsome Therapeutics positions in Q2 2023 and 16 closed out, a net change of +34 holders.
  • The largest Axsome Therapeutics buyer in Q2 2023 was RA Capital Management, an estimated $73.8M added.
  • The largest Axsome Therapeutics seller in Q2 2023 was Point72 Asset Management, an estimated $51.8M sold.

Based on aggregated 13F filings for Q2 2023.